# Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation

> **NCT01596075** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Rabin Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Cannabidiol

## Key facts

- **NCT ID:** NCT01596075
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01596075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01596075, "Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT01596075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*